

31. (New) The mouse of Claim 30, wherein the skin lesions are on the ears of the mouse.

32. (New) The mouse of Claim 31, wherein the skin lesions are at least one member selected from the group consisting of erythema, edema, excoriation, and scaling.

33. (New) The mouse of Claim 31, wherein the skin lesions are erythema.

34. (New) The mouse of Claim 29, wherein the symptom is ear swelling.

35. (New) A method of producing the mouse of Claim 21, comprising:
maintaining a NC/Nga mouse in a Specific Pathogen Free environment and
impregnating the mouse with the mite extract.

36. (New) The method of Claim 25, wherein the animal is impregnated with the mite extract for at least 5 days.

37. (New) A method of screening for an agent for effectiveness against an allergic disorder, comprising:

applying at least one agent to the mouse of Claim 29,
determining whether the agent reduced the allergy symptom and/or in vitro disorder,
correlating a reduction in the allergy symptom and/or in vitro disorder with
effectiveness against the allergic disorder, and

correlating a lack of reduction in the allergy symptom and/or in vitro disorder with
ineffectiveness against the allergic disorder.

38. (New) The method of Claim 37, wherein the allergic disorder is selected from the group consisting of atopic dermatitis, atopic asthma, conjunctival allergy, allergic rhinitis, food allergy, urticaria, contact dermatitis, allergic reactions to drugs, anaphylaxis, autoimmune disease, organ transplant rejection and allo- or xeno-tissue transplant rejection.--